Literature DB >> 8759066

Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study.

B Lamarche1, S Moorjani, P J Lupien, B Cantin, P M Bernard, G R Dagenais, J P Després.   

Abstract

BACKGROUND: Results obtained largely from case-control studies have suggested that an elevated plasma concentration of apolipoprotein (apo) B may be considered an important risk factor for ischemic heart disease (IHD). Prospective data on the relevance of measuring apo A-I and apo B levels in the assessment of IHD risk, however, remain sparse as well as controversial. METHODS AND
RESULTS: Plasma lipid, apo B, and apo A-I levels as well as other risk factors were evaluated at baseline in 1985 in a sample of 2155 men (45 to 76 years old) who were followed for a period of 5 years for clinical signs of IHD. Proportional-hazards analyses indicated that plasma apo B concentrations measured at entry were strongly associated with onset of IHD (relative rate, 1.4; 95% confidence interval [CI], 1.2 to 1.7), independent of covariables such as age, smoking, diabetes mellitus, and systolic blood pressure. Controlling for triglycerides, HDL cholesterol, and total/HDL cholesterol ratio did not eliminate the relationship between plasma apo B levels and IHD. The association between apo A-I and IHD was of lower magnitude (relative rate, 0.85; 95% CI, 0.7 to 1.0), and adjustment for selected plasma lipid and lipoprotein levels eliminated this association. Stepwise logistic regression analysis revealed that, among metabolic variables, apo B was the strongest correlate of IHD.
CONCLUSIONS: These prospective results emphasize the importance of apo B as a risk factor for IHD. Apo B may be regarded as a relevant tool in the assessment of IHD risk in men, because it may provide information that would not be obtained from the conventional lipid-lipoprotein profile.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8759066     DOI: 10.1161/01.cir.94.3.273

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  53 in total

1.  Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS/TexCAPS trial.

Authors:  A D Sniderman; J Bergeron; J Frohlich
Journal:  CMAJ       Date:  2001-01-09       Impact factor: 8.262

Review 2.  Obesity, hypertension, and vascular disease.

Authors:  K M Sowers; J R Sowers
Journal:  Curr Hypertens Rep       Date:  1999 Apr-May       Impact factor: 5.369

3.  Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid-chromatography-multiple- reaction-monitoring mass spectrometry.

Authors:  Sean A Agger; Luke C Marney; Andrew N Hoofnagle
Journal:  Clin Chem       Date:  2010-10-05       Impact factor: 8.327

4.  Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples.

Authors:  Oemer-Necmi Goek; Anna Köttgen; Ron C Hoogeveen; Christie M Ballantyne; Josef Coresh; Brad C Astor
Journal:  Nephrol Dial Transplant       Date:  2012-01-28       Impact factor: 5.992

5.  Prothrombotic markers in asymptomatic dyslipidemic subjects.

Authors:  David Karasek; Helena Vaverkova; Milan Halenka; Dagmar Jackuliakova; Zdenek Frysak; Ludek Slavik; Dalibor Novotny
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

6.  A study of serum apolipoprotein A1, apolipoprotein B and lipid profile in stroke.

Authors:  Shilpasree As; Savitri Sahukar; Jayaprakash Murthy; Kiran Kumar
Journal:  J Clin Diagn Res       Date:  2013-07-01

7.  Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.

Authors:  Ruth McPherson; Jiri Frohlich; George Fodor; Jacques Genest
Journal:  Can J Cardiol       Date:  2006-09       Impact factor: 5.223

Review 8.  Lipid parameters for measuring risk of cardiovascular disease.

Authors:  Benoit J Arsenault; S Matthijs Boekholdt; John J P Kastelein
Journal:  Nat Rev Cardiol       Date:  2011-02-01       Impact factor: 32.419

9.  Discrimination of ischemic and hemorrhagic strokes using a multiplexed, mass spectrometry-based assay for serum apolipoproteins coupled to multi-marker ROC algorithm.

Authors:  Mary F Lopez; David A Sarracino; Amol Prakash; Michael Athanas; Bryan Krastins; Taha Rezai; Jennifer N Sutton; Scott Peterman; Oksana Gvozdyak; Sherry Chou; Eng Lo; Ferdinand Buonanno; MingMing Ning
Journal:  Proteomics Clin Appl       Date:  2012-04       Impact factor: 3.494

Review 10.  New dimension of statin action on ApoB atherogenicity.

Authors:  M John Chapman; Muriel Caslake; Chris Packard; Fergus McTaggart
Journal:  Clin Cardiol       Date:  2003-01       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.